NCT01673854 - Phase II Safety Study of Vemurafenib Followed by Ipilimumab in Subjects With V600 BRAF Mutated Advanced Melanoma | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 13, 2012

Primary Completion Date

July 25, 2014

Study Completion Date

May 12, 2015

Conditions

Melanoma

Interventions

DRUG

Ipilimumab

BIOLOGICAL

Vemurafenib

Trial Locations (14)

Mount Sinai School Of Medicine, New York

Duke University Hospital, Durham

Dumc, Durham

Levine Cancer Institute, Charlotte

Winship Cancer Institute, Atlanta

Baptist Cancer Institute, Jacksonville

Orlando Health, Inc, Orlando

University Hospitals Of Cleveland, Cleveland

University Hospitals, Cleveland

Karmanos Cancer Institute, Detroit

University Of New Mexico Cancer Center, Albuquerque

Beverly Hills Cancer Center, Beverly Hills

Dana Farber Cancer Institute, Boston

Dana-Farber Cancer Institute, Boston